These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35156207)

  • 1. Bioenergetic remodeling in the pathophysiology and treatment of nonalcoholic fatty liver disease.
    Azul AM; Winter M; Silva D; Georgievska L; Oliveira PJ
    Eur J Clin Invest; 2022 Mar; 52(3):e13749. PubMed ID: 35156207
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nonalcoholic fatty liver disease. Pathophysiologically oriented diagnosis and therapy].
    Ströhle A; Stein J
    Med Monatsschr Pharm; 2015 May; 38(5):166-78; quiz 179-80. PubMed ID: 26364406
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update.
    Assunção SNF; Sorte NCB; Alves CD; Mendes PSA; Alves CRB; Silva LR
    Nutr Hosp; 2017 Jun; 34(3):727-730. PubMed ID: 28627213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    ; LaBrecque DR; Abbas Z; Anania F; Ferenci P; Khan AG; Goh KL; Hamid SS; Isakov V; Lizarzabal M; Peñaranda MM; Ramos JF; Sarin S; Stimac D; Thomson AB; Umar M; Krabshuis J; LeMair A;
    J Clin Gastroenterol; 2014 Jul; 48(6):467-73. PubMed ID: 24921212
    [No Abstract]   [Full Text] [Related]  

  • 7. The Mexican consensus on nonalcoholic fatty liver disease.
    Bernal-Reyes R; Castro-Narro G; Malé-Velázquez R; Carmona-Sánchez R; González-Huezo MS; García-Juárez I; Chávez-Tapia N; Aguilar-Salinas C; Aiza-Haddad I; Ballesteros-Amozurrutia MA; Bosques-Padilla F; Castillo-Barradas M; Chávez-Barrera JA; Cisneros-Garza L; Flores-Calderón J; García-Compeán D; Gutiérrez-Grobe Y; Higuera de la Tijera MF; Kershenobich-Stalnikowitz D; Ladrón de Guevara-Cetina L; Lizardi-Cervera J; López-Cossio JA; Martínez-Vázquez S; Márquez-Guillén E; Méndez-Sánchez N; Moreno-Alcantar R; Poo-Ramírez JL; Ramos-Martínez P; Rodríguez-Hernández H; Sánchez-Ávila JF; Stoopen-Rometti M; Torre-Delgadillo A; Torres-Villalobos G; Trejo-Estrada R; Uribe-Esquivel M; Velarde-Ruiz Velasco JA
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(1):69-99. PubMed ID: 30711302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.
    Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):115-116. PubMed ID: 31971024
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?
    Michel M; Schattenberg JM
    Expert Opin Investig Drugs; 2020 Feb; 29(2):93-97. PubMed ID: 31933385
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease.
    Masarone M; Rosato V; Dallio M; Gravina AG; Aglitti A; Loguercio C; Federico A; Persico M
    Oxid Med Cell Longev; 2018; 2018():9547613. PubMed ID: 29991976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAFLD: The evolving landscape.
    George J; Anstee Q; Ratziu V; Sanyal A
    J Hepatol; 2018 Feb; 68(2):227-229. PubMed ID: 29223512
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue.
    Kwanten WJ; Martinet W; Michielsen PP; Francque SM
    World J Gastroenterol; 2014 Jun; 20(23):7325-38. PubMed ID: 24966603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease in children and adolescents.
    Penke M; Kiess W; Giorgis T
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1329-1330. PubMed ID: 27861140
    [No Abstract]   [Full Text] [Related]  

  • 17. [Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016].
    Chen YS; Wang BY; Li YM
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):181-186. PubMed ID: 28482404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAFLD vs NAFLD: Where are we?
    Mantovani A
    Dig Liver Dis; 2021 Oct; 53(10):1368-1372. PubMed ID: 34108096
    [No Abstract]   [Full Text] [Related]  

  • 19. The Effects of Physical Exercise on Fatty Liver Disease.
    van der Windt DJ; Sud V; Zhang H; Tsung A; Huang H
    Gene Expr; 2018 May; 18(2):89-101. PubMed ID: 29212576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery.
    Selby LV; Ejaz A; Brethauer SA; Pawlik TM
    Expert Opin Investig Drugs; 2020 Feb; 29(2):107-110. PubMed ID: 31986920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.